233 related articles for article (PubMed ID: 16597210)
1. HIV/AIDS pathogenesis and treatment options focusing on the viral entry inhibitors.
Jones R; Gazzard B
Expert Rev Anti Infect Ther; 2006 Apr; 4(2):303-12. PubMed ID: 16597210
[TBL] [Abstract][Full Text] [Related]
2. The role of receptors in the HIV-1 entry process.
Jones R; Nelson M
Eur J Med Res; 2007 Oct; 12(9):391-6. PubMed ID: 17933719
[TBL] [Abstract][Full Text] [Related]
3. Building the best regimen for highly treatment-experienced patients.
Nelson MR
J HIV Ther; 2002 Nov; 7(4):102-5. PubMed ID: 12733609
[TBL] [Abstract][Full Text] [Related]
4. Current status and challenges of antiretroviral research and therapy.
Esté JA; Cihlar T
Antiviral Res; 2010 Jan; 85(1):25-33. PubMed ID: 20018390
[TBL] [Abstract][Full Text] [Related]
5. Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status.
Kwara A; Flanigan TP; Carter EJ
Int J Tuberc Lung Dis; 2005 Mar; 9(3):248-57. PubMed ID: 15786886
[TBL] [Abstract][Full Text] [Related]
6. [Antiretroviral therapy in 2004].
Jablonowski H
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():46-8, 50-1. PubMed ID: 15373049
[TBL] [Abstract][Full Text] [Related]
7. Antiretroviral therapy in HIV.
Yu A; Berbari E; Temesgen Z
J Med Liban; 2006; 54(2):74-9. PubMed ID: 17086997
[TBL] [Abstract][Full Text] [Related]
8. Emerging resistance profiles of newly approved antiretroviral drugs.
Daar ES
Top HIV Med; 2008; 16(4):110-6. PubMed ID: 18838744
[TBL] [Abstract][Full Text] [Related]
9. Long-Term suppression of HIV infection: benefits and limitations of current treatment options.
Sension MG
J Assoc Nurses AIDS Care; 2007; 18(1 Suppl):S2-10. PubMed ID: 17275719
[TBL] [Abstract][Full Text] [Related]
10. [New kinds of AIDS drugs inhibit HIV entry into the cell. Entry inhibitors soon for oral administration].
Fätkenheuer G
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():46-8. PubMed ID: 16385874
[TBL] [Abstract][Full Text] [Related]
11. The impact of HIV-1 subtype on the clinical response on HAART.
Frater J
J HIV Ther; 2002 Nov; 7(4):92-6. PubMed ID: 12733607
[TBL] [Abstract][Full Text] [Related]
12. The future of antiretroviral therapy: challenges and needs.
Moreno S; López Aldeguer J; Arribas JR; Domingo P; Iribarren JA; Ribera E; Rivero A; Pulido F;
J Antimicrob Chemother; 2010 May; 65(5):827-35. PubMed ID: 20228080
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 dynamics in vivo: implications for therapy.
Simon V; Ho DD
Nat Rev Microbiol; 2003 Dec; 1(3):181-90. PubMed ID: 15035022
[TBL] [Abstract][Full Text] [Related]
14. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients.
Napravnik S; Keys JR; Quinlivan EB; Wohl DA; Mikeal OV; Eron JJ
AIDS; 2007 Apr; 21(7):825-34. PubMed ID: 17415037
[TBL] [Abstract][Full Text] [Related]
15. "Solving the puzzle" of current HAART: what key strategic trials are needed?
Carosi G; Torti C
New Microbiol; 2004 Apr; 27(2 Suppl 1):127-30. PubMed ID: 15646075
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral therapy: a primer for dermatologists.
Kim HN; Harrington RD
Dermatol Clin; 2006 Oct; 24(4):537-47, vii. PubMed ID: 17010782
[TBL] [Abstract][Full Text] [Related]
17. Drug resistance among chronic HIV-1-infected patients naïve for use of anti-retroviral therapy in Sao Paulo city.
Gonsalez CR; Alcalde R; Nishiya A; Barreto CC; Silva FE; de Almeida A; Mendonça M; Ferreira F; Fernandes SS; Casseb J; Duarte AJ
Virus Res; 2007 Nov; 129(2):87-90. PubMed ID: 17686543
[TBL] [Abstract][Full Text] [Related]
18. Continued correspondence 'Will ART rollout in Africa drive an epidemic of drug-resistant HIV?'.
Hastings IM; Lalloo DG; Khoo SH
AIDS; 2007 Jan; 21(2):258-9; author reply 259-60. PubMed ID: 17197825
[No Abstract] [Full Text] [Related]
19. Case files from Stanford University Medical Center: ten years of HAART: a long wait for full HIV suppression.
Shulman N; Shafer RW
MedGenMed; 2007 Jan; 9(1):10. PubMed ID: 17435619
[No Abstract] [Full Text] [Related]
20. Trends in the European HIV/AIDS epidemic: a perspective from Italy.
Madeddu G; Rezza G; Mura MS
Expert Rev Anti Infect Ther; 2009 Feb; 7(1):25-36. PubMed ID: 19622055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
